Overview

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer